Tempest Therapeutics
Tempest Therapeutics
TPST
NASDAQ
0.85
USD
2.41%
About
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495.
TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC).
The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 799.7K |
| Three Month Average Volume | 62.3M |
| High Low | |
| Fifty-Two Week High | 9.77 USD |
| Fifty-Two Week Low | 0.17 USD |
| Fifty-Two Week High Date | 11 Oct 2023 |
| Fifty-Two Week Low Date | 10 Oct 2023 |
| Price and Volume | |
| Current Price | 1.29 USD |
| Beta | -2 |
| Relative Price Change | |
| Four Week Relative Price Change | -22.72% |
| Thirteen Week Relative Price Change | -63.70% |
| Twenty-Six Week Relative Price Change | -68.12% |
| Fifty-Two Week Relative Price Change | 91.35% |
| Year-to-Date Relative Price Change | -75.24% |
| Price Change | |
| One Day Price Change | -4.44% |
| Thirteen Week Price Change | -61.14% |
| Twenty-Six Week Price Change | -64.95% |
| Five Day Price Change | -9.15% |
| Fifty-Two Week Price Change | 139.78% |
| Year-to-Date Price Change | -70.68% |
| Month-to-Date Price Change | -27.53% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.21423 USD |
| Book Value Per Share (Most Recent Quarter) | 0.69207 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.21423 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.69207 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.59438 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.91299 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.64472 USD |
| Normalized (Last Fiscal Year) | -1.91299 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.91299 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.64472 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.91299 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.64472 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.77952 USD |
| Cash Per Share (Most Recent Quarter) | 1.27162 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.88827 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.59877 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.31557 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -56.69% |
| Tangible Book Value (5 Year) | -17.71% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 36.40% |
| Total Debt (5 Year) | 79.13% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 21.04% |
| EPS Change (Trailing Twelve Months) | 31.77% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -20,471,000 |
| Net Debt (Last Fiscal Year) | -28,681,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 23 |
| Long Term Debt to Equity (Most Recent Quarter) | 12 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -27,527,000 |
| Free Cash Flow (Trailing Twelve Months) | -25,782,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -87 |
| Net Interest Coverage (Trailing Twelve Months) | -368 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 39 |
| Total Debt to Equity (Most Recent Quarter) | 63 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -60.38% |
| Return on Assets (Trailing Twelve Months) | -87.09% |
| Return on Assets (5 Year) | -57.10% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -131.42% |
| Return on Equity (Trailing Twelve Months) | -289.26% |
| Return on Equity (5 Year) | -89.62% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -72.81% |
| Return on Investment (Trailing Twelve Months) | -127.72% |
| Return on Investment (5 Year) | -71.20% |